(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.76%.
Quoin Pharmaceuticals's earnings in 2025 is -$13,767,556.On average, 5 Wall Street analysts forecast QNRX's earnings for 2025 to be -$518,260,158, with the lowest QNRX earnings forecast at -$745,897,155, and the highest QNRX earnings forecast at -$357,655,712. On average, 4 Wall Street analysts forecast QNRX's earnings for 2026 to be -$186,597,618, with the lowest QNRX earnings forecast at -$198,848,354, and the highest QNRX earnings forecast at -$171,119,759.
In 2027, QNRX is forecast to generate -$15,574,761 in earnings, with the lowest earnings forecast at -$14,963,986 and the highest earnings forecast at -$16,032,842.